近年来，嵌合抗原受体-T（CAR-T）细胞疗法已成为一种新型的免疫治疗方法。它在治疗血液 B 细胞恶性肿瘤方面显示出显着的疗效。特别是针对CD19的CAR-T疗法对急性B淋巴细胞白血病（B-ALL）和非霍奇金淋巴瘤（NHL）产生了前所未有的疗效。在血液系统恶性肿瘤中，肿瘤干细胞更容易停留在调节性骨髓（BM）微环境（称为生态位）中，这提供了抵抗免疫攻击的保护环境。然而，BM微环境如何影响CAR-T细胞的抗肿瘤功效及其潜在机制值得关注。在这篇综述中，我们讨论了骨髓微环境对 CAR-T 治疗血液恶性肿瘤疗效的作用，并提出了相应的策略来增强 CAR-T 疗法的抗肿瘤活性。© 2023 斯堪的纳维亚免疫学基金会。

In recent years, chimeric antigen receptor-T (CAR-T) cell therapy has emerged as a novel immunotherapy method. It has shown significant therapeutic efficacy in the treatment of haematological B cell malignancies. In particular, the CAR-T therapy targeting CD19 has yielded unprecedented efficacy for acute B-lymphocytic leukaemia (B-ALL) and non-Hodgkin's lymphoma (NHL). In haematologic malignancies, tumour stem cells are more prone to stay in the regulatory bone marrow (BM) microenvironment (called niches), which provides a protective environment against immune attack. However, how the BM microenvironment affects the anti-tumour efficacy of CAR-T cells and its underlying mechanism is worthy of attention. In this review, we discuss the role of the BM microenvironment on the efficacy of CAR-T in haematological malignancies and propose corresponding strategies to enhance the anti-tumour activity of CAR-T therapy.© 2023 The Scandinavian Foundation for Immunology.